Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease

维多利祖马布 先天免疫系统 医学 免疫学 免疫 炎症性肠病 获得性免疫系统 免疫系统 内科学 疾病
作者
Sebastian Zeißig,Elisa Rosati,C. Marie Dowds,Konrad Aden,Johannes Bethge,Berenice Schulte,Wei Hung Pan,Neha Mishra,Maaz Zuhayra,Marlies Marx,Maren Paulsen,Anne Strigli,Claudio Cim Conrad,Dörthe Schuldt,Anupam N. Sinha,Henriette Ebsen,Sabin-Christin Kornell,Susanna Nikolaus,Alexander Arlt,Dieter Kabelitz
出处
期刊:Gut [BMJ]
卷期号:68 (1): 25-39 被引量:215
标识
DOI:10.1136/gutjnl-2018-316023
摘要

OBJECTIVE: Vedolizumab, a monoclonal antibody directed against the integrin heterodimer α4β7, is approved for the treatment of Crohn's disease and ulcerative colitis. The efficacy of vedolizumab has been suggested to result from inhibition of intestinal T cell trafficking although human data to support this conclusion are scarce. We therefore performed a comprehensive analysis of vedolizumab-induced alterations in mucosal and systemic immunity in patients with inflammatory bowel disease (IBD), using anti-inflammatory therapy with the TNFα antibody infliximab as control. DESIGN: Immunophenotyping, immunohistochemistry, T cell receptor profiling and RNA sequencing were performed using blood and colonic biopsies from patients with IBD before and during treatment with vedolizumab (n=18) or, as control, the anti-TNFα antibody infliximab (n=20). Leucocyte trafficking in vivo was assessed using single photon emission computed tomography and endomicroscopy. RESULTS: Vedolizumab was not associated with alterations in the abundance or phenotype of lamina propria T cells and did not affect the mucosal T cell repertoire or leucocyte trafficking in vivo. Surprisingly, however, α4β7 antibody treatment was associated with substantial effects on innate immunity including changes in macrophage populations and pronounced alterations in the expression of molecules involved in microbial sensing, chemoattraction and regulation of the innate effector response. These effects were specific to vedolizumab, not observed in response to the TNFα antibody infliximab, and associated with inhibition of intestinal inflammation. CONCLUSION: Our findings suggest that modulation of innate immunity contributes to the therapeutic efficacy of vedolizumab in IBD. TRIAL REGISTRATION NUMBER: NCT02694588.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
蛋蛋发布了新的文献求助10
刚刚
刚刚
刚刚
Esthaeique发布了新的文献求助10
1秒前
1秒前
追寻的淇发布了新的文献求助10
1秒前
YUNshu发布了新的文献求助10
2秒前
2秒前
3秒前
路奇k发布了新的文献求助10
3秒前
Cr的应助被张靖雯采纳,获得10
4秒前
今后的应助被背后的念烟采纳,获得10
4秒前
orixero的应助被研友_闾丘枫采纳,获得10
5秒前
小透明发布了新的文献求助10
5秒前
LiPengpeng完成签到,获得积分10
6秒前
ilucce发布了新的文献求助10
7秒前
7秒前
yj发布了新的文献求助10
9秒前
杨钧贺发布了新的文献求助20
9秒前
小王完成签到,获得积分10
9秒前
9秒前
11秒前
qingwan完成签到,获得积分20
12秒前
华无剑的应助被yyy采纳,获得10
12秒前
ikji发布了新的文献求助30
13秒前
理穆辛完成签到 ,获得积分10
13秒前
14秒前
小酒完成签到,获得积分10
14秒前
Akim的应助被wwww采纳,获得10
14秒前
zhangwenkang发布了新的文献求助30
14秒前
桃子完成签到,获得积分10
15秒前
arT完成签到,获得积分10
15秒前
16秒前
深情安青的应助被勤奋一一采纳,获得10
16秒前
17秒前
17秒前
17秒前
爆米花的应助被JIA采纳,获得10
18秒前
18秒前
CTbnun完成签到,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Markov Decision Processes and Reinforcement Learning 700
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8171099
求助须知:如何正确求助?哪些是违规求助? 9563824
关于积分的说明 21772514
捐赠科研通 7762641
什么是DOI,文献DOI怎么找? 3430786
关于科研通互助平台的介绍 2554704
邀请新用户注册赠送积分活动 2475690